Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  IBA  /  Forum IBA geopend

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel IBA BRU:IBAB.BL, BE0003766806

  • 13,080 25 apr 2024 16:24
  • -0,220 (-1,65%) Dagrange 13,000 - 13,340
  • 10.445 Gem. (3M) 52,3K

Forum IBA geopend

987 Posts
Pagina: «« 1 ... 11 12 13 14 15 ... 50 »» | Laatste | Omlaag ↓
  1. forum rang 5 Endless 17 april 2018 13:13
    quote:

    jeff_cassius schreef op 17 april 2018 10:57:

    [...]

    Mooi stukje over de samenwerking mer RaySearch.
    De koers reageert er wel negatief op......
    weet je ik beleg al langere tijd en soms snap ik de koersen nog steeds niet. of deze gedrukt worden door grotere partijen ik weet het niet. wat ik wel geleerd heb om een mooi koopmoment te herkennen zoals vandaag. Uitstekend product. Zijn wereldleider. daarbij de koersval omdat het even vorig jaar tegen zat. de orders waren omdat het een grote investering betreft nog niet afgekomen. Ik heb dus maar bijgekocht en leg ze op de plank.
  12. forum rang 5 Endless 25 april 2018 16:07
    Press release |


    IBA Logo
    IBA installs cyclotron at first proton therapy center in Belgium


    ParTICLe Proton Therapy Center completes a key construction milestone with the arrival of the centerpiece cyclotron

    Louvain-la-Neuve, 25 April, 2018 – IBA (Ion Beam Applications S.A.), the world’s leading provider of proton therapy solutions for the treatment of cancer, and UZ Leuven, today announce the installation of the first proton therapy units at the University Hospitals Leuven (UZ Leuven). This is the first phase of installation of the IBA Proteus®ONE system, the most advanced proton therapy technology. This proton therapy center, the first to be installed in Belgium, is scheduled to begin treating patients in the second half of 2019.

    Arriving from the nearby IBA headquarters in Louvain-la-Neuve, Belgium, the installation of the 55-ton synchrocyclotron was completed this morning at UZ Leuven's Gasthuisberg campus. The new cyclotron is part of a new generation system that is smaller and more affordable than other proton therapy systems. The leading edge single room Proteus®ONE system includes advanced robotics, integrated imaging, and control systems.

    Proton therapy is considered to be the most advanced form of radiotherapy in the fight against cancer. The unique dose deposition that proton therapy offers enables the tumor to be targeted more effectively than other treatments. Compared to photon radiotherapy, protons deposit almost all their energy within a controlled zone and in the vast majority of cases, limit the amount of the dose deposited in the healthy tissue surrounding the tumor. The use of protons consequently offers the potential to reduce the secondary effects of the treatment.

    Olivier Legrain, Chief Executive Officer of IBA, commented: “We are delighted to start the installation of the first proton therapy center in Belgium. We are proud that our innovative technology is being deployed so close to our headquarters and that our high-quality cancer treatment will now be available for cancer patients in Belgium. We look forward to collaborating with the consortium of leading university hospitals on this project.”

    Marc Decramer, Chief Executive Officer of UZ Leuven commented: “We are excited to see the heart of our proton therapy center delivered. Today, Belgian patients eligible for proton therapy have to go abroad to be treated. By the second half of 2019, the first patients will be able to receive treatment in the Particle Therapy Interuniversity Center Leuven (ParTICLe).


    ***Ends***


    About IBA
    IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.
    IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
    More information can be found at: www.iba-worldwide.com

    *Proteus®ONE is the brand name of a configuration of the Proteus®235.


    Official pictures available here.

    For further information please contact:

    IBA
    Thomas Ralet
    Head of Corporate Communication
    Tel.: +32 10 47 58 90
    communication@iba-group.com






    IBA | Chemin du cyclotron 3 | 1348 Louvain-la-Neuve | Belgium | Phone: +32 10 201 275 | www.iba-worldwide.com
    To ensure delivery of IBA emails to your inbox, we kindly request that you add investorrelations@iba-group.com to your address book.







  14. R8kever 27 april 2018 11:17
    United States Proton Therapy Market 2009-2018 & 2024 - Patients by 14 Cancer Types, Reimbursement Policies & Persons Treated at Centers
    Dublin, April 27, 2018 (GLOBE NEWSWIRE) -- The "United States Proton Therapy Market, Patients by 14 Cancer Types, Reimbursement Policies & Persons Treated at Centers" report has been added to ResearchAndMarkets.com's offering

    United States proton therapy market has potential to surpass US$ 16 Billion by the end of 2024
  15. Valère 27 april 2018 18:00
    als nieuweling -belegger snap ik dit (nog) niet zo goed ... IBA komt in het VTM nieuws met het plaatsen van een protontoestel , hetgeen toch positief nieuws is ,veronderstel ik , en als reactie ...dalende koers . Toen Ablynx met gelijk welk nieuws uitpakte , steeg de koers ( en het volume ) ... Rara...
  16. forum rang 5 Endless 3 mei 2018 07:50
    IBA selected to install new proton therapy center in Italy

    Term sheet signed with the European Institute of Oncology (IEO) to install a Proteus®ONE compact proton therapy solution in Milan


    Louvain-La-Neuve, Belgium, 3 May 2018 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that after an in-depth selection process, it has been selected as preferred vendor by the European Institute of Oncology (IEO) to install a Proteus®ONE* compact proton therapy solution in Milan, Italy. This will be IBA’s 22nd installation of its compact single-room proton therapy solution.

    IEO and IBA signed a binding term sheet with a down payment for the delivery of a Proteus®ONE solution, including IBA’s latest generation Pencil Beam Scanning (PBS), isocenter volumetric imaging (Cone Beam CT) capabilities and a long-term operation and maintenance agreement. The hospital expects to start treating patients by the end of 2020. The typical end-user price for a Proteus®ONE system with a maintenance contract is between EUR 35 and 40 million. IBA and IEO have agreed to work in good faith to complete negotiations of the Final Agreement by year-end.

    Olivier Legrain, Chief Executive Officer of IBA, commented: “We are delighted that IBA has been chosen by the European Institute of Oncology to build its proton therapy center which strengthens our world leading position in proton therapy and demonstrates IBA’s superior product offering in the market. Our Proteus®ONE solution is a unique truly compact intensity modulated proton therapy (IMPT) system and alongside its open gantry and track record of short installation time is the solution of choice for an increasing number of hospitals in all regions of the world. We look forward to collaborating with IEO to provide greater access to proton therapy for cancer patients in Italy.”

    Mr Mauro Melis, Chief Executive Officer of IEO, commented: “The European Institute of Oncology is today a reference point in research and cancer care, both at the national and European level. The IEO Advanced Radiotherapy Center in particular is ranked amongst the top five centers in Europe for technology equipment and number of patients treated. With the new Proton Center we will contribute to the development of international clinical studies on the clinical use of proton therapy, and at the same time we will expand our state-of-the-art offering of cancer therapies. It is therefore important for us to partner with IBA to bring the world’s leading proton beam therapy equipment to more cancer patients in Italy.”

    Prof. Roberto Orecchia, Scientific Director of IEO, said: “Proton therapy is a superior form of radiotherapy and nowadays represents a new and better chance of treatment for many cancer forms in children and adults. However, there is still a lot we have to discover about proton therapy. An important value of entering into a partnership with IBA is to become part of its impressive proton therapy user community and to participate in its research collaborations. We are convinced that proton therapy will gain importance in the fight against cancer. Worldwide estimates indicate that 20% of cancer patients could benefit from this treatment, whereas today only 0.8 % of radiotherapy patients receive proton therapy.”

    ***ENDS***


    About Proteus®ONE
    Proteus®ONE is the compact intensity modulated proton therapy (IMPT) solution from IBA. It benefits from the latest technologies developed with renowned clinical institutions. Proteus®ONE is smaller, more affordable, easier to install and to operate. It is ultimately easier to finance, making this advanced radiation therapy modality available to more institutions and patients worldwide. Proteus®ONE makes proton therapy easy.

    * Proteus®ONE is the brand name of Proteus®235

    About IBA
    IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

    IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

    More information can be found at: www.iba-worldwide.com

    About IEO (European Institute of Oncology)
    The European Institute of Oncology (Istituto Europeo di Oncologia – IEO) strives for excellence in cancer prevention, early diagnosis and effective treatment. We aim to achieve this through clinical and scientific research development, organisational and management innovation, with a constant focus on the quality of the service provided to the patients.

    The IEO staff are driven and inspired by the following values and principles:
    Patient focus
    Continuous healthcare quality improvement
    Service excellence
    Multidisciplinary approach to clinical care
    Participation in trial research and rapid transfer of results to the patients
    Enhancing the value of human resources
    European spirit and openness to international collaborations
  17. JACKY CHAN 3 mei 2018 08:00
    quote:

    Valère schreef op 27 april 2018 18:00:

    als nieuweling -belegger snap ik dit (nog) niet zo goed ... IBA komt in het VTM nieuws met het plaatsen van een protontoestel , hetgeen toch positief nieuws is ,veronderstel ik , en als reactie ...dalende koers . Toen Ablynx met gelijk welk nieuws uitpakte , steeg de koers ( en het volume ) ... Rara...
    Het is ook het aandeel van de shorters.
  19. Traumabulls 3 mei 2018 09:02
    iba-worldwide.com/content/iba-selecte...

    Proton therapy
    /
    03.05.2018

    Term sheet signed with the European Institute of Oncology (IEO) to install a Proteus®ONE compact proton therapy solution in Milan

    Louvain-La-Neuve, Belgium, 3 May 2018 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that after an in-depth selection process, it has been selected as preferred vendor by the European Institute of Oncology (IEO) to install a Proteus®ONE* compact proton therapy solution in Milan, Italy. This will be IBA’s 22nd installation of its compact single-room proton therapy solution.

    IEO and IBA signed a binding term sheet with a down payment for the delivery of a Proteus®ONE solution, including IBA’s latest generation Pencil Beam Scanning (PBS), isocenter volumetric imaging (Cone Beam CT) capabilities and a long-term operation and maintenance agreement. The hospital expects to start treating patients by the end of 2020. The typical end-user price for a Proteus®ONE system with a maintenance contract is between EUR 35 and 40 million. IBA and IEO have agreed to work in good faith to complete negotiations of the Final Agreement by year-end.

    Olivier Legrain, Chief Executive Officer of IBA, commented: “We are delighted that IBA has been chosen by the European Institute of Oncology to build its proton therapy center which strengthens our world leading position in proton therapy and demonstrates IBA’s superior product offering in the market. Our Proteus®ONE solution is a unique truly compact intensity modulated proton therapy (IMPT) system and alongside its open gantry and track record of short installation time is the solution of choice for an increasing number of hospitals in all regions of the world. We look forward to collaborating with IEO to provide greater access to proton therapy for cancer patients in Italy.”

    Mr Mauro Melis, Chief Executive Officer of IEO, commented: “The European Institute of Oncology is today a reference point in research and cancer care, both at the national and European level. The IEO Advanced Radiotherapy Center in particular is ranked amongst the top five centers in Europe for technology equipment and number of patients treated. With the new Proton Center we will contribute to the development of international clinical studies on the clinical use of proton therapy, and at the same time we will expand our state-of-the-art offering of cancer therapies. It is therefore important for us to partner with IBA to bring the world’s leading proton beam therapy equipment to more cancer patients in Italy.”

    Prof. Roberto Orecchia, Scientific Director of IEO, said: “Proton therapy is a superior form of radiotherapy and nowadays represents a new and better chance of treatment for many cancer forms in children and adults. However, there is still a lot we have to discover about proton therapy. An important value of entering into a partnership with IBA is to become part of its impressive proton therapy user community and to participate in its research collaborations. We are convinced that proton therapy will gain importance in the fight against cancer. Worldwide estimates indicate that 20% of cancer patients could benefit from this treatment, whereas today only 0.8 % of radiotherapy patients receive proton therapy.”
987 Posts
Pagina: «« 1 ... 11 12 13 14 15 ... 50 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!